Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(22):1666-1668; doi:10.1093/jnci/94.22.1666
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 22, 1666-1668, November 20, 2002
© 2002 Oxford University Press

NEWS

Synthetic Lethality: Killing Cancer With Cancer

Ken Garber

The first 10% of the full text of this article appears below.

The surge of optimism for new cancer drugs that target cell signaling pathways has been tempered by a dose of reality. Some patients taking Gleevec (imatinib mesylate) have developed resistance to the drug as a result of mutations in the bcr-abl fusion protein or gene amplification. The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee recently recommended AstraZeneca’s Iressa (gefitinib) for accelerated approval for third-line therapy for non-small cell lung cancer, but with strong reservations; a large phase III trial of the drug—which targets the epidermal growth factor receptor—resulted in no improvement in survival (see News, Nov. 6, p. 1596). And Pharmacia’s SU5416, which targets the vascular endothelial growth factor receptor, was abandoned in February after extensive phase II and phase III testing.

Thus far, signaling inhibitors have not proven to be a panacea, and researchers are wondering whether the problem is in the target . . . [Full Text of this Article]

Lethal Combination

Cancer Unmasked

House of Cards


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
J. R. Rohde, S. Campbell, S. A. Zurita-Martinez, N. S. Cutler, M. Ashe, and M. E. Cardenas
TOR Controls Transcriptional and Translational Programs via Sap-Sit4 Protein Phosphatase Signaling Effectors
Mol. Cell. Biol., October 1, 2004; 24(19): 8332 - 8341.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
L. Kopelovich, J. A. Crowell, and J. R. Fay
The Epigenome as a Target for Cancer Chemoprevention
J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. Geneve
Re: Demand Grows for Early Access to Promising Cancer Drugs
J Natl Cancer Inst, March 19, 2003; 95(6): 492 - 492.
[Full Text] [PDF]